FDA Warns Oft-Quoted Dermatologist For Promoting Investigational Drug
This article was originally published in The Rose Sheet
Executive Summary
FDA's recent warning letter to prominent dermatologist Leslie Baumann for her remarks promoting a not-yet-approved Botox alternative makes a statement early in the year about the rigor the agency is bringing to its public safety mission